Introduction
Evidence suggests that inflammation influences bone turnover and hence may contribute to the aetiopathogenesis of osteoporosis [1] , a disease characterized by reduced bone mineral density (BMD) and disruption of bone microarchitecture, resulting in increased risk of fracture.
There is a close relationship between the immune and skeletal systems [2] and epidemiological studies have demonstrated an increased risk of developing osteoporosis in inflammatory conditions such as ankylosing spondylitis [3] , rheumatoid arthritis [4] and inflammatory bowel disease [5] . In addition, pro--inflammatory cytokines have been associated with osteoblast and osteoclast regulation, and with bone resorption [6] .
However, inflammation is also a part of the aging process, possibly due to the increased production of pro--inflammatory cytokines mediated through estrogen--regulated pathways, consistent with observations that bone loss at menopause is associated with low grade inflammation [7] . Although the mechanisms are not fully understood, systemic inflammation can affect bone remodeling, leading to adverse effects on bone structure and strength [8] .
Based on the hypothesis that age related low--grade inflammation influences bone phenotypes, we have evaluated candidate genes with a putative role in inflammation--induced modulation of bone tissue, skeletal integrity and fracture risk.
The 17p13 region of the human genome contains quantitative trait loci regulating BMD [9] . This region, which was also identified in an early meta--analysis of genome wide association studies (GWAS) for femoral neck BMD [10] , includes the genes encoding arachidonate 12--lipoxygenase (ALOX12) and arachidonate 15--lipoxygenase (ALOX15). Lipid metabolites are produced from the polyunsaturated arachidonic acid [11] , some of which have pro--inflammatory effects [12] and have been suggested to play role in chronic inflammation [13] .
In experimental studies ALOX15--knockout mice have higher BMD and bone strength compared to wild type mice, suggesting ALOX15 to be a negative regulator of BMD [14] .
Epidemiological studies have reported associations, albeit inconsistent, between genetic variation in both the ALOX12 and ALOX15 genes and bone properties [15--20] , and with body Page 4 of 20 composition and fat mass [21, 22] . Strengthening their putative role as candidate genes for osteoporosis, ALOX12/15 metabolites can act as ligands for peroxisome proliferator--activated receptor gamma (PPARγ) [23] . Activation of PPARγ--dependent pathways promotes adipogenesis at the expense of osteoblastogenesis, promotes osteoclast differentiation [24] and has an proinflammatory role [25] . Metabolites generated by ALOX12/15 also directly activate expression of the proinflammatory cytokine interleukin 6 (IL--6) [12] , whose levels are elevated in inflammatory states [26] . Polymorphisms in IL6 and PPARG have been associated with osteoporosis [27--31] .
This study investigates polymorphisms in ALOX12, ALOX15, IL6 and PPARG genes in relation to osteoporosis associated phenotypes. Reflecting the temporal aspect of age--related inflammation, the study has been performed in young and elderly Swedish women. The phenotypes investigated comprehensively reflect bone microstructure and strength. In the elderly women we also investigated the relationship between these genes and the most commonly used biomarker of inflammation, the acute phase reactant C--reactive protein (CRP).
Materials and methods

Subjects
Two population based cohorts of Swedish women were studied. The Malmö Osteoporotic
Prospective Risk Assessment (OPRA) cohort consists of 1044 elderly women all aged 75 years and prospectively followed for 10 years, and the PEAK--25 cohort consists of 1061 women all aged 25 years. Details of these two cohorts have been published previously [32, 33] .
Participants gave written informed consent and the study was approved by the Regional Ethical Review Board in Lund and performed according to the principles of the Helsinki agreement. spine, total hip and total body. Fat and lean mass for total body was also measured with the same instruments. Calibrations were performed daily using a manufacturer supplied phantom. The precision error (coefficient of variation) was 0.94%, 1.45%, 4.01% for total body, lumbar spine and femoral neck, respectively in the OPRA cohort [34] , and 0.90% and 0.65% for femoral neck and lumbar spine, respectively in the PEAK--25 cohort [35] . Bone loss was calculated in the OPRA cohort as BMD at 5 year follow--up minus BMD at baseline.
Measurement of bone phenotypes and body composition
Quantitative ultrasound measurements (QUS), i.e. speed of sound (SoS), broadband ultrasound attenuation (BUA) and stiffness index (SI), were performed on the right calcaneus using the Lunar Achilles® system (Lunar Corporation, Madison, WI, USA). Precision was 1.5
for BUA and SoS [36] . Calibrations were performed daily.
Trabecular bone score (TBS) index is a novel approach applied to DXA images to estimate bone microstructure. Due to technical limitations TBS could not be calculated from the Lunar DPX--L, therefore spine acquisitions were available only for the PEAK--25 cohort. These were analyzed using the manufacture's provided software (Encore 2004; GE medical--Lunar,
Madison, WI) and a standardized protocol was followed for assessment of TBS indexing [37] .
TBS was calculated as the mean value of the individual measurements for each vertebra (L1 to L4).
Incident Fractures
For the OPRA cohort, information on fractures was continuously registered through the X--rays files at the Radiology Department, Malmö, Skåne University Hospital. Incident fracture data was collected until October 31 st 2012, providing a maximum follow--up for fracture of 17.2 years (mean 13.1 years). In this paper we analyse 'any incident fracture' which includes hip, distal radius, vertebra, shoulder, pelvis and proximal tibia. The majority of fractures recorded were attributable to low energy trauma [38] . Excluded were fractures of the face, hands and feet and fractures resulting from pathology and high energy trauma.
Analysis of C--reactive protein
CRP measurements were available only in the OPRA cohort. Blood samples were centrifuged and stored at --80°C. CRP was analyzed by routine methods using Roche Diagnostics (Cobas). Page 6 of 20
The lowest detectable limit was 0.6 mg/L and coefficient of variation (CV) 3.6 -4.1. CRP levels >10 mg/ml was assumed to result from acute inflammation and subsequently 77 women were excluded from the analysis. Since the lowest detectable limit for CRP was 0.6 mg/L, missing (undetectable) values were imputed [39] .
Genotyping
Total genomic DNA was isolated from blood using the QIAamp 96 DNA blood kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions.
Three single nucleotide polymorphisms (SNPs) in ALOX12, five SNPs in ALOX15 and one SNP each in IL--6 and PPARG were genotyped in both cohorts (Table 1) although PPARγ was available only for a proportion of PEAK--25 (n=472). The rationale for SNP selection at the time when genotyping was performed is outlined below. SNPs for ALOX12 were selected from the literature as having been previously investigated for BMD [16, 18, 20] . SNP rs312466
is located in the promoter, while rs1126667 and rs2292350 are NCBI tagging SNPs located in an LD block [16] . For ALOX15, with the exception of rs8074545 upstream of the coding region (which is intergenic and therefore has potential functionality) all selected SNPs were tagging SNPs previously investigated for BMD (rs748694; rs9894225; rs916055; rs2619112) [20] . The IL--6 tagging SNP rs10242595, located downstream of the coding region was selected for its previous association with decreased fat mass [40] while PPARγ rs1801282 (Pro12Ala) is the most extensively examined in a variety of diseases including osteoporosis [31] .
Genotyping of the Pro12Ala PPARγ SNP used restriction enzyme analysis of PCR amplified DNA and gel electrophoresis. All other genotyping was performed using iPlex (Sequenom, HapMap (Table 1 ). All SNPs, except for rs1801282_PPARγ in the OPRA cohort (p=0.013) due to a slightly higher than predicted rare allele frequency, conformed to Hardy Weinberg Equilibrium.
Statistical analysis
Statistical analyses were performed using SPSS version 22 (IBM Corp., NY, USA) and associations with a p--value of <0.05 were considered nominally significant. The phenotypes and several of the markers studied are not independent (i.e. are correlated or in linkage disequilibrium), therefore applying a Bonferroni correction would be over--stringent. We therefore report the uncorrected p--values and acknowledge the fact that multiple tests were performed.
Using a co--dominant model (comparing the three genotypes, under the assumption that neither of the alleles is dominant), genotype specific differences between the phenotypes were analyzed by ANOVA. Association adjusting for confounding factors (body weight, height, smoking) was performed using regression analysis. To facilitate comparison with other published studies, the rs748694_ALOX15 was also analysed as carriage of the common T allele (i.e. TT, TC versus CC). The χ2 test was used to analyze genotype differences in fracture incidence.
Results
Characteristics of the participants from the two cohorts are shown in Table S1 . As expected, the young PEAK--25 women had higher BMD and QUS values compared to the elderly women in the OPRA cohort, while total body fat was higher in the OPRA cohort.
In neither of the two cohorts were ALOX12 SNPs associated with BMD, bone microarchitecture or fracture (data not shown). In PEAK--25, a nominal association with spine BMD did not withstand adjustment for weight, height and smoking. Table 2 ), suggesting that the relationship with calcaneal microarchitecture is independent of bone density. No association was seen with trabecular architecture (TBS) however (Table 2) . While there was a trend towards lower bone density among those carrying at least one copy of the 'T' allele, this was weak (total body BMD, p=0.046) or non--significant (Table 2 ).
In the elderly OPRA participants, ALOX15 SNPs were not associated with QUS or BMD.
Women with 1 or 2 copies of the rare G allele of rs2619112_ALOX15 had a trend towards higher incidence of fractures of any type sustained after the age of 75. However, this was not mirrored in the relationship with bone density or ultrasound phenotypes (data not shown). Excluding women receiving treatment for osteoporosis (estrogen or bisphosphonates (n=48)) did not appreciably alter the results.
The variant allele of IL6_rs10242595 was associated with lower BMD in the PEAK--25 but not the OPRA cohort and there were no associations with other bone phenotypes in either the young or elderly women (Table 3) .
Variation in PPARG was not associated with bone phenotypes in either cohort (data not shown).
Bone loss, only calculated in the elderly women, was not associated with any of the analyzed variants in ALOX12, ALOX15, IL6 or PPARG (Table S2) .
Body composition i.e. fat and lean mass, did not differ according to ALOX12, IL6 or PPARG genotype in either of the cohorts. For ALOX15 no association was observed with body composition in the PEAK--25 cohort, while in OPRA, an association was seen for rs8074545_ALOX15 with total body fat (25536 ± 7811 / 26983 ± 7956 / 25550 ± 7294; p = 0.026), and remained significant after adjustment for height (data not shown).
Serum levels of CRP showed a allele dependent increase with the highest levels in homozygotes for the common A allele of rs2619112_ALOX15 (baseline p = 0.004; 5--year Page 9 of 20 follow up (p=0.035) ( Table  4) . Polymorphisms in ALOX12, IL--6 or PPARγ were not associated with levels of CRP (data not shown).
Discussion
In this study, we analysed the association between polymorphisms in ALOX12, ALOX15, IL6 and PPARG with bone phenotypes and with the inflammatory biomarker CRP. We used the candidate gene approach since GWAS is not definitive in identifying all the genetic variation contributing to complex disease phenotypes. There is ample evidence of a role for the selected genes in regulation of inflammation and bone remodeling. The results from our study suggest an association, albeit weak, between genetic variation in the ALOX15 gene and altered serum levels of CRP in 75--year old women. This appears to support the hypothesis of a pro--inflammatory role of the ALOX15 pathway in humans, although in our cohorts, polymorphisms in ALOX15 do not appear to play a direct role in skeletal integrity in older women, while apparently influencing bone microarchitecture in young women. While other studies have investigated the association between ALOX15 and bone in pre--and post--menopausal women these were in cohorts of different ethnicities and with a focus only on BMD [15, 19] . In the present study we aimed at investigating the role of ALOX15 polymorphisms using cohorts with a homogeneous genetic background and investigating phenotypes reflecting skeletal integrity and fracture risk. A variant in ALOX15, located in the promoter and thus potentially functional was associated, independent of bone density, with higher quantitative ultrasound values in the young women. This indicates a role for ALOX15 in skeletal microarchitecture, although this was not confirmed by the spine trabecular bone score data. We can only speculate the extent to which differential loading patterns at these skeletal sites may have contributed to these observations. In the elderly women the results appear contradictory; no appreciable genotype related differences on BMD or QUS yet a tendency towards higher fracture incidence despite lower CRP levels. We interpret these observations to support a role for ALOX15 in modulating inflammatory cytokines [12] while suggesting that fractures are not directly related to increased inflammatory activity, at least not as reflected by serum CRP levels [39] . Unfortunately, other inflammatory biomarkers were not available and neither fracture nor CRP was available in PEAK--25, which is an undoubted limitation of the study. We found that ALOX12 polymorphisms were associated with BMD only in the young but not the elderly women, contradicting the low BMD and increased vertebral fracture risk among post--menopausal women observed in another study [18] . The much higher age at inclusion of the women in the OPRA cohort leads us to conjecture whether ALOX12 may be most important during critical periods of high bone turnover, for example during bone accrual and menopause.
In PEAK--25 IL6 was associated with lower femoral neck and spine BMD, which is supported by previous studies reporting association with BMD, ultrasound and fractures in women and men [27--30] . The same SNP has also been associated with decreased fat mass in men [40] . In the present study, there was no association between IL6 and bone properties in the elderly women, although previously a functional promoter polymorphism (rs1800795), which increased IL--6 promoter activity and plasma IL--6 levels, was weakly correlated with lower QUS values and fracture [30] . Adipose tissue is a source of inflammatory cytokines and PPARG is widely associated with type II diabetes and concomitant obesity. Association between PPARG and lower BMD has previously been reported in pre-- and post--menopausal women [31, 41] , however our results suggest PPARG variation is not a major player in the regulation of bone strength, which may reflect ethnic differences between Japanese and Swedish populations as well as the analysis of different SNPs.
The low grade inflammatory state characteristic of aging was the background on which we hoped to better understand the role of inflammation associated genes in bone regulation. Our results only partially realize this ambition and require cautious interpretation as the observed associations are modest. Disappointingly, we conclude that the analysed SNPs in ALOX12, ALOX15, IL--6 or PPARG do not appear to make a major contribution to bone phenotypes at very advanced ages, while in young adult women ALOX15 and IL6 were associated with bone density and microarchitecture. Potential associations could be masked by gene--gene interactions (which were out with the scope of this study to address) or by the fact that both pro--and anti--inflammatory metabolites are generated by ALOX12/15 pathways and could modulate bone phenotypes [42] .
The present study has its limitations, among them the fact that that the SNPs were not identified from GWAS, but rather selected from the literature. On the other hand, SNP based GWAS do not identify all disease risk variants. Many variants conferring a small risk are overlooked and many SNPs falling below the accepted threshold of statistical significance may be relevant when investigated through pathway analyses [43, 44] . Another limitation is that not all phenotypes were available in both cohorts, which in the case of the TBS data, introduces some uncertainty as to what extent bone microarchitecture rather than bone density is influenced. To better understand the contribution of inflammation related genes during the life--course it would be interesting to compare the very elderly women with women in early post--menopause as it may be that potential associations are masked, due to the long time since estrogen withdrawal or by underlying comorbidities. Page 11 of 20 In summary, we found that variation in inflammation related genes ALOX15 and IL6 was associated with bone density and microarchitecture in young adult women although the role of these genes in the pathogenesis of osteoporosis in the very elderly is less easy to interpret. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
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